• Save
©aquir / 123RF Stock Photo

FDA approved a broadened indication of afatinib in the 1st-line treatment of metastatic NSCLC with non-resistant EGFR mutations

/0 Comments/in /by

 

 

You might also like
U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer
  • Save
US FDA approved immune-checkpoint inhibitors updated 05-Jun-2020
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency Adjuvant sunitinib FDA approved for renal cell carcinoma patients at high risk of recurrence following nephrectomy.
  • Save
Sotorasib for the treatment of KRASG12C mutated lung cancer
Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC
  • Save
Lenvatinib FDA approved for 1st-line treatment of HCC
Front-line atezolizumab plus chemotherapy improves PFS in NSCLC
  • Save
Frontline atezolizumab plus chemotherapy improves PFS in NSCLC
  • Save
Trastuzumab/hyaluronidase-oysk subcutaneous formulation FDA approved for HER2‑overexpressing breast cancer
ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC
  • Save
ASCO 2020 Lung, Breast, and Liver Cancer Update
More Information.  June 19, 2018">
  • Save
More Information.  June 19, 2018" alt="FDA  has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.  More Information.  June 19, 2018" height="180" width="180" srcset="https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-180x180.jpg 180w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-80x80.jpg 80w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-36x36.jpg 36w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-120x120.jpg 120w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-450x450.jpg 450w" sizes="(max-width: 180px) 100vw, 180px"> FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply